ENGAGE AF-TIMI 48 data show that BMI was negatively associated with risk of stroke/SEE and positively associated with risk of bleeding, although sex differences were seen.
In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.
Higher LDL-c associates with EOAD, independently of APOE E4. Novel rare genetic coding variants were found in APOB, which do not fully explain the association between high LDL-c and EOAD.
In the follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.
An analysis of the ASCOT-LLA trial showed similar associations of non-fasting and fasting lipid levels with CV events in the same individuals, with high concordance for ASCVD risk categorization based on non-fasting and fasting lipid levels.
CLARIFY registry data suggest that beta-blocker use was only associated with lower 5-year mortality in patients enrolled in the year following in MI. Use of calcium antagonists did not impact mortality.
The Heart Failure Association of the ESC has published a clinical practice update on pharmacotherapy, procedures, devices and patient management of heart failure.
Prof. Adriaan Voors addresses 3 major questions on the future of SGLT2i in HF: on routinely use in T2DM and HF, use in HF without T2DM, and ongoing trials.
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.
ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.
EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.
EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.